Hero Response Expands Its Restoration Services to Ontario with Two New Locations
Hero Response, a nationally recognized full-service restoration leader, has announced the expansion of its operations to include two new locations in Ontario. This move underscores...
ABVC BioPharma and OncoX BioPharma Strengthen Oncology Collaboration with $100,000 Milestone Payment
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has announced the receipt of a $100,000 milestone payment from OncoX BioPharma, Inc., marking a significant step in...
GeoVax Revises Gedeptin® Clinical Strategy Following KEYNOTE-689 Trial Results
GeoVax Labs, Inc. has announced a significant update to its Gedeptin® clinical development program, shifting focus towards evaluating Gedeptin as a neoadjuvant therapy in combination...
The First Washington Monument in Boonsboro MD: A Historical and Artistic Legacy
The Washington Monument in Boonsboro, MD, holds the distinction of being the first monument in the United States erected in honor of George Washington. Completed...
Miami’s Parking Landscape Evolves Amid Rapid Growth and Technological Advancements
The parking landscape in Miami is undergoing significant changes due to the city’s rapid population growth and increasing tourism, necessitating innovative solutions to meet the...
SolarBank Corporation Rebrands as PowerBank Corporation to Reflect Expanded Energy Focus
SolarBank Corporation, known on the NASDAQ as SUUN, Cboe CA as SUNN, and FSE as GY2, has announced its rebranding to PowerBank Corporation, effective July...
Energy Fuels Inc. Announces Q2 2025 Financial Results Conference Call
Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), a prominent U.S. producer of uranium, rare earth elements, and critical minerals, has scheduled a conference call...
Mullen Automotive Inc. Rebrands to Bollinger Innovations, Signaling Strategic Shift
Mullen Automotive Inc. (NASDAQ: MULN), a prominent electric vehicle manufacturer, is set to undergo a significant rebranding, changing its name to Bollinger Innovations, Inc. starting...
Candel Therapeutics’ CAN-2409 Receives European Orphan Designation for Pancreatic Cancer Treatment
Candel Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced that the European Medicines Agency (EMA) has granted Orphan Designation for its drug CAN-2409, aimed at...